Novo Nordisk | NVO - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
ANI Pharmaceuticals USD 94.86M 3.2M 2026-09
Aurora Cannabis CAD 40.89M 515K 2026-06
Bausch Health Companies USD 834M 67M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Canopy Growth CAD 33.99M 2.83M 2026-06
Corcept Therapeutics USD 142.04M 14.86M 2026-09
Drreddys Laboratories INR 28.08B 13.61B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
GlaxoSmithKline GBP 2.16B 39M 2026-09
Merck USD 2.86B 25M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.08B 163M 2026-09
Novo Nordisk DKK 16.31B 3.09B 2026-06
Novo Nordisk DKK 2.54B 10.68B 2026-06
Pacira USD 950.8M 858.99M 2026-09
Perrigo USD 271.7M 3.01B 2026-09
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 2.08B 2.04B 2026-09
Sanofi EUR 2.31B 325M 2026-09
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
Zoetis USD 582M 10M 2026-09